Actavis and Teva sued over narcotic addiction generic

Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone (buprenorphine and naloxone) and Subutex (buprenorphine).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Teva drops lawsuit with Amicus over Creates Act dispute

7 September 2021 Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.

Generics

Fed Circ upholds three Teva patents, axes others

19 August 2021 The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Actavis and Teva sued over narcotic addiction generic

More on this story

Editor's picks

Editor's picks

More features